Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Non-Current Debt (2024 - 2025)

Apellis Pharmaceuticals has reported Non-Current Debt over the past 2 years, most recently at $361.7 million for Q4 2025.

  • Quarterly results put Non-Current Debt at $361.7 million for Q4 2025, up 0.61% from a year ago — trailing twelve months through Dec 2025 was $361.7 million (up 0.61% YoY), and the annual figure for FY2025 was $361.7 million, up 0.61%.
  • Non-Current Debt for Q4 2025 was $361.7 million at Apellis Pharmaceuticals, roughly flat from $361.1 million in the prior quarter.
  • Over the last five years, Non-Current Debt for APLS hit a ceiling of $364.0 million in Q2 2024 and a floor of $359.0 million in Q3 2024.